Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Bushnell D, Menda Y, O'Dorisio T, Madsen M, Miller S, Carlisle T, Squires S, Kahn D, Walkner W, Connolly M, O'Dorisio S, Karwal M, Ponto J, Bouterfa H.
Bushnell D, et al. Among authors: menda y.
Cancer Biother Radiopharm. 2004 Feb;19(1):35-41. doi: 10.1089/108497804773391658.
Cancer Biother Radiopharm. 2004.
PMID: 15068609
Clinical Trial.